Matthew F. McManus

BIO-TECHNE Corp (TECH)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Matthew F. McManus

BIO-TECHNE Corp reported in an 8-K filed January 8, 2024 that Matthew F. McManus was appointed President, Diagnostics and Genomics Segment, effective January 8, 2024.

“Bio-Techne Corporation (NASDAQ: TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024.”

BIO-TECHNE Corp Form 8-K, filed January 8, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Research with Equibles

Turn this profile into a cited research brief

Start with a question tailored to the filings and events on this page, or connect Equibles financial data to ChatGPT or Claude.

Suggested question: “Summarize Matthew F. McManus's recent executive appointments or departures and cite the source filings.”

Use in your AI

Affiliation history

Recorded current and former roles; source labels appear when available.

BIO-TECHNE Corp (TECH)
SEC 8-K

Current
2024-01-08–present

Company network

Recorded roles and call appearances connecting this person to public companies.

BIO-TECHNE Corp

TECH

Current role

Leadership on record at BIO-TECHNE Corp

Other people whose current roles at this company are on record from its filings.

Charles Kummeth CEO
James T. Hippel CFO
Kim Kelderman COO, Board Member
Shane Bohnen General Counsel
Alpna Seth Board Member
Amy Herr Board Member
Charles R. Kummeth Board Member
Dr. Amy Herr Board Member
Dr. Judith Klimovsky Board Member
John L. Higgins Board Member

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Executive change Appointed: President, Diagnostics and Genomics Segment BIO-TECHNE Corp (TECH)
2024-01-08